文献速递妇科产科生殖医学

跨性别人群中的乳腺与生殖系统癌症:一项系统综述

Breast and reproductive cancers in the transgender population: a systematic review.
PubMed 文献 · BJOG · 2018-05-29

该系统综述检索五个数据库共获得228篇文章,纳入43篇,评估跨性别人群乳腺与生殖系统癌症的患病率及性别肯定激素与风险的关系。总体证据质量为极低至低。跨性别女性报告20例乳腺癌、2例新阴道癌、1例睾丸癌和8例前列腺癌;跨性别男性报告18例乳腺癌、5例卵巢癌、4例子宫/宫颈癌和1例阴道癌。现有证据不足以估计患病率,性别肯定激素对癌症风险的影响尚未得到证实,但明确需要设计良好的稳健研究来确认或反驳。

要点

  • 跨性别女性报告20例乳腺癌、2例新阴道癌、1例睾丸癌和8例前列腺癌。
  • 跨性别男性报告18例乳腺癌、5例卵巢癌、4例子宫/宫颈癌和1例阴道癌。
  • 现有证据不足以估计跨性别人群乳腺或生殖系统癌症的患病率。

核心结论

  • 现有证据不足以估计跨性别人群乳腺或生殖系统癌症的患病率。
  • 性别肯定激素尚未被证明影响癌症风险,但明确需要设计良好的稳健研究来确认或反驳。

研究设计与样本

  • 系统综述,检索方案在PROSPERO注册后检索五个数据库,由两名评价者筛选文献。
  • 纳入研究调查跨性别人群的乳腺、卵巢、子宫、宫颈、阴道、新阴道、睾丸和前列腺癌,排除二次研究、意见、社论和会议摘要,无日期、语言或环境限制。
  • 文献检索获得228篇文章,纳入43篇,按研究人群(跨性别男性/跨性别女性)和癌症类型进行分类、汇总和分析。
  • 总体证据质量为极低至低。

主要发现

  • 跨性别女性中报告20例乳腺癌、2例新阴道癌、1例睾丸癌和8例前列腺癌。
  • 跨性别男性中报告18例乳腺癌、5例卵巢癌、4例子宫/宫颈癌和1例阴道癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 总体证据质量为极低至低。
  • 现有证据不足以估计跨性别人群乳腺或生殖系统癌症的患病率。
  • 性别肯定激素对癌症风险的影响尚未被证明,明确需要设计良好的稳健研究来确认或反驳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The medical transition undergone by a transgender person may influence their risk of breast or reproductive cancer. OBJECTIVES: To assess breast and reproductive cancer prevalence in the transgender population. To elucidate any associations between gender-affirming hormones and risk of these cancers. SEARCH STRATEGY: Following registration of review protocol with PROSPERO, five databases were searched. SELECTION CRITERIA: Included studies investigated breast, ovarian, uterine, cervical, vaginal, neovaginal, testicular and prostate cancer in the transgender population. Secondary studies, opinions, editorials and conference abstracts were excluded. No date, language or setting restrictions were applied. DATA COLLECTION AND ANALYSIS: Two reviewers conducted literature searches and applied inclusion and exclusion criteria to the results. Studies were categorised, aggregated and analysed by study population (transmen/transwomen) and type of cancer. MAIN RESULTS: The literature search produced 228 articles; 43 were included. The overall evidence quality was very low to low. In transgender women, 20 breast cancer cases, two neovaginal cancer cases, one testicular cancer case and eight prostate cancer cases were reported. In transgender men, 18 breast cancer cases, five ovarian cancer cases, four uterine/cervical cancer cases and one vaginal cancer case were reported. CONCLUSIONS: There is insufficient evidence to estimate breast or reproductive cancer prevalence in the transgender population. Gender-affirming hormones have not been shown to affect cancer risk, but there is a clear need for well-designed, robust studies to confirm or refute this. FUNDING: This study was undertaken as an education dissertation. No funding was received. TWEETABLE ABSTRACT: Little is known about the impact of gender-affirming hormones on breast or reproductive cancers in trans people.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Joint R, Chen ZE, Cameron S, et al. Breast and reproductive cancers in the transgender population: a systematic review. BJOG. 2018. PMID: 29706033. doi:10.1111/1471-0528.15258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。